Clinical Trials on Oxybutynin in Hong Kong
Total 0 results
Nothing found
Sponsors and Collaborators
- AIDS Council of New South Wales
- Chengdu Nuoen Biotechnologies, Inc.
- InflaRx GmbH
- Maria Lendorf
- Nestor Soler Porcar, MD, PhD
- Mononuclear Therapeutics Ltd.
- Centro di Procreazione Assistita Demetra
- ImproveCareNow (ICN)
- Neuregenix
- Veeda Oncology
- Prestige Biopharma Limited
- BayCare Health System
- Bruce County Paramedic Service
- Bjørgene Omsorgssenter, Haugesund
- North Karelia Hospital District
- Yantai Yuhuangding Hospital，Medical College, Qingdao University
- Equipe MiMes
- Women and children's hospital of Jiaxing university
- Grand Challenges Canada
- Reina Sofia University Hospital
- View Full List
Medical Conditions
- Fetus or Neonate Affected by External Version Before Labor
- Childhood Langerhans Cell Histiocytosis
- Predictors of Atrial Fibrillation Recurrences
- Cutaneous Leiomyomata With Uterine Leiomyomata
- Closure; Foramen Ovale
- Painless Hysteroscopy
- Fracture Dislocation of Cervical Spine
- Endocarditis Infective
- Gullian Barre Syndrome
- Tay-Sachs Disease Ganglioside
- Spine Surgeries
- Pulmonary Adenocarcinoma
- Chlamydophila Infections
- Multisystem Proteinopathy
- Ewing's Family Tumors
- Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura
- Epidemic Hemorrhagic Fever
- Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase
- Psoriasis, Arthritic
- Skull Base Neoplasms
- View Full List
Drug Interventions
- Neihulizumab
- Azelastine hydrochloride (BAYR9258)
- Adriamycin
- Vehicle
- Redifferentiation with retinoid acid
- NanoDoce (intravesical instillation) - Induction and Maintenance Instillations
- Esomeprazole 40mg before
- Estradiol+Drospirenone
- Adapalene Gel 0.3%
- Chemotherapeutic Agent
- EFV +TVA
- Palliative care group first-line scheme
- Naltrexone 50 mg/day + Cognitive Behavioral Therapy
- Glimepiride
- Cereport
- Qingkailing injection 40 ml
- Semapimod
- High dose pantoprazole infusion
- PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714
- Mocetinostat - Recommended Phase 2 Dose (70 mg)
- View Full List
CROs by country
- Contract Research Organizations in Algeria
- Contract Research Organizations in Bulgaria
- Contract Research Organizations in China
- Contract Research Organizations in Equatorial Guinea
- Contract Research Organizations in Guinea
- Contract Research Organizations in Israel
- Contract Research Organizations in Latvia
- Contract Research Organizations in Luxembourg
- Contract Research Organizations in Mali
- Contract Research Organizations in Malta
- Contract Research Organizations in Mongolia
- Contract Research Organizations in Mozambique
- Contract Research Organizations in Slovakia
- CRO list by country